• Japanese
  • Korean
  • Chinese
Cover Image

LY2189265 (Type 2 Diabetes) - Analysis and Forecasts to 2020

Abstract

LY2189265 (Type 2 Diabetes) - Analysis and Forecasts to 2020

Summary

GlobalData's pharmaceuticals report, "LY2189265 (Type 2 Diabetes) - Analysis and Forecasts to 2020" provides LY2189265 sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2014-2020). The report also includes information on Type 2 Diabetes market. This report is built using data and information sourced from GlobalData's proprietary databases, primary and secondary research using Company's corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of LY2189265 including historical sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of LY2189265 including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2014-2020 for LY2189265 in each of the seven major markets

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drug's performance
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

TOC

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 4
  • 1.2 List of Figures 4

2 Introduction 5

  • 2.1 Diabetes 5
  • 2.2 Epidemiology 5
    • 2.2.1 Prevalence 5
    • 2.2.2 Mortality 7
  • 2.3 Etiology and Risk Factors 9
    • 2.3.1 Obesity 9
    • 2.3.2 Sedentary Lifestyle 9
    • 2.3.3 Family History and Genetics 9
    • 2.3.4 Ethnicity 9
    • 2.3.5 Old Age 9
  • 2.4 Economic Impact of Diabetes 9
  • 2.5 GlobalData Report Guidance 11

3 Type 2 Diabetes: Market Characterization 12

  • 3.1 Type 2 Diabetes Market 12
  • 3.2 Type 2 Diabetes Market Forecasts 13
  • 3.3 Type 2 Diabetes Market: Drivers and Restraints 14
    • 3.3.1 Drivers 14
    • 3.3.2 Restraints 15

4 Classification of Diabetes 16

  • 4.1 Types of Diabetes 16
    • 4.1.1 Type 1 Diabetes 16
    • 4.1.2 Type 2 Diabetes 16
    • 4.1.3 Gestational Diabetes 16
  • 4.2 Diabetes Complications 16
    • 4.2.1 Cardiovascular Disease 16
    • 4.2.2 Nephropathy 17
    • 4.2.3 Neuropathy 17
    • 4.2.4 Amputation 17
    • 4.2.5 Retinopathy 17

5 Evolution of Anti-Diabetic Treatments 18

6 Medications 19

  • 6.1 Insulin 19
  • 6.2 Oral Medications 19
    • 6.2.1 Sulfonylureas (SUR) 19
    • 6.2.2 Biguanides (BGDs) 20
    • 6.2.3 Alpha-Glucosidase Inhibitors (AGI) 21
    • 6.2.4 Meglitinides 21
    • 6.2.5 Thiazolidinediones (TZDs) 22
    • 6.2.6 Dipeptidyl Peptidase IV (DPP- 4) Inhibitors 23
    • 6.2.7 Oral Combination Therapy 23
  • 6.3 Other Injectionable Medications 24
    • 6.3.1 Pramlintide 24
    • 6.3.2 Exenatide 24
  • 6.4 Market Share as per Classes in Type 2 Diabetes 24

7 LY2189265 25

  • 7.1 Introduction 25
  • 7.2 Mechanism of Action 25
  • 7.3 Clinical Studies 25
    • 7.3.1 Phase II 25
    • 7.3.2 Phase III 25
  • 7.4 Factors Affecting Sales of LY2189265 26
    • 7.4.1 Once Weekly Dosage 26
    • 7.4.2 Competition from Januvia 26
    • 7.4.3 Approval of Bydureon 26
  • 7.5 Drug Evaluation 26
    • 7.5.1 Drug Risk Benefit Score 26
    • 7.5.2 Intensity of Competition 27
  • 7.6 Sales Forecasts 27
    • 7.6.1 Target Patient Pool for LY2189265 27
    • 7.6.2 Dosing 27
    • 7.6.3 Market Penetration 28
    • 7.6.4 Annual Cost of Therapy 29
    • 7.6.5 Sales Projections of LY2189265 30

8 Diabetes Market: Appendix 39

  • 8.1 Market Definitions 39
  • 8.2 List of Abberiviations 39
  • 8.3 Research Methodology 39
    • 8.3.1 Coverage 39
    • 8.3.2 Secondary Research 40
    • 8.3.3 Forecasting 40
    • 8.3.4 Number of patients approved to take the drug 40
    • 8.3.5 Net Penetration of Drug 41
    • 8.3.6 Net Annual Dosing 41
    • 8.3.7 Annual Cost of Therapy 41
  • 8.4 Drug Sales Estimates Model 41
  • 8.5 Contact Us 41
  • 8.6 Disclaimer 41
  • 8.7 Sources 42

List of Tables

1.1 List of Tables

  • Table 1: Diabetes, World, Prevalence Estimates for the age group 20-79 years (million), 2000-2030 5
  • Table 2: Diabetes, Top 10 Countries, by Prevalence (million), 2010 and 2030 7
  • Table 3: Diabetes, Top 10 Countries, Highest Health Expenditures ($bn), 2010 10
  • Table 4: Type 2 Diabetes, World, Major Marketed Drugs by Sales ($m), 2010 12
  • Table 5: Type 2 Diabetes, World, Major Pipeline Products in Phase III Clinical Trials 13
  • Table 6: Diabetes, Worldwide, Prevalence Estimates, 2010 and 2030 14
  • Table 7: Overweight*, Global, Prevalence Estimates in Males Aged 15 and above (%), 2005 15
  • Table 8: Diabetes Drugs Evolution 18
  • Table 9: Drug Risk Benefit Score of LY2189265 26
  • Table 10: Estimated Annual Cost of Therapy of LY189265, 2014 29
  • Table 11: LY2189265, Type 2 Diabetes, Global, Sales Forecasts ($m), 2014-2020 30
  • Table 12: LY2189265, Type 2 Diabetes, The US, Sales Forecasts ($m), 2014-2020 31
  • Table 13: LY2189265, Type 2 Diabetes, The UK, Sales Forecasts ($m), 2014-2020 32
  • Table 14: LY2189265, Type 2 Diabetes, France, Sales Forecasts ($m), 2014-2020 33
  • Table 15: LY2189265, Type 2 Diabetes, Germany, Sales Forecasts ($m), 2014-2020 34
  • Table 16: LY2189265, Type 2 Diabetes, Italy, Sales Forecasts ($m), 2014-2020 35
  • Table 17: LY2189265, Type 2 Diabetes, Spain, Sales Forecasts ($m), 2014-2020 36
  • Table 18: LY2189265, Type 2 Diabetes, Japan, Sales Forecasts ($m), 2016-2020 37

List of Figures

1.2 List of Figures

  • Figure 1: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2010 6
  • Figure 2: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2030 6
  • Figure 3: Diabetes, World, Mortality, 2010 7
  • Figure 4: Top 10 Causes of Mortality, Worldwide, 2008 8
  • Figure 5: Type 2 Diabetes, Global, Market Size Forecasts ($bn), 2010-2020 13
  • Figure 6: Mechanism of Action of Sulfonylureas 19
  • Figure 7: Mechanism of Action of Biguanide, Thiazolidinediones, Alpha-Glucosidase Inhibitors 20
  • Figure 8: Mechanism of Action of Metformin and Alpha-Glucosidase Inhibitors 21
  • Figure 9: Mechanism of Action of Thiazolidinediones 22
  • Figure 10: Mechanism of Action of DPP IV Inhibitors 23
  • Figure 11: Type 2 Diabetes, Global, Branded Market Share by Value, By Class (%), 2010 24
  • Figure 12: LY2189265, Type 2 Diabetes, Global, Sales Forecasts ($m), 2014-2020 30
  • Figure 13: LY2189265, Type 2 Diabetes, The US, Sales Forecasts ($m), 2014-2020 31
  • Figure 14: LY2189265, Type 2 Diabetes, The UK, Sales Forecasts ($m), 2014-2020 32
  • Figure 15: LY2189265, Type 2 Diabetes, France, Sales Forecasts ($m), 2014-2020 33
  • Figure 16: LY2189265, Type 2 Diabetes, Germany, Sales Forecasts ($m), 2014-2020 34
  • Figure 17: LY2189265, Type 2 Diabetes, Italy, Sales Forecasts ($m), 2012-2020 35
  • Figure 18: LY2189265, Type 2 Diabetes, Spain, Sales Forecasts ($m), 2014-2020 36
  • Figure 19: LY2189265, Type 2 Diabetes, Japan, Sales Forecasts ($m), 2016-2020 37
  • Figure 20: LY2189265, Type 2 Diabetes, Global, Sales Distribution (%), 2020 38
  • Figure 21: Patients Approved for the Drug 40
Show More
Pricing
Get Notified
Email me when related reports are published